



FOR IMMEDIATE RELEASE

**JMAR Technologies Releases BioSentry
Designed for High-Purity Water Applications**

New System to be tested in Pharmaceutical Manufacturing Application

SAN DIEGO, CA (January 15, 2007) – JMAR Technologies, Inc. (OTCBB: JMAR), a leading developer of advanced laser, photonics and detection technologies, today announced a new release of its flagship sensor product, the BioSentry™, which has been engineered specifically for use in pharmaceutical manufacturing and other high-purity water applications.

BioSentry™ is a water monitoring system that provides early contamination warning from waterborne microorganisms. Whereas current water monitoring depends on grab sampling of water and time-consuming lab analysis, BioSentry uses laser-based technology to provide continuous, on-line, real-time monitoring of harmful bacteria. Initially, BioSentry targeted applications in homeland security, the beverage industry, and municipal drinking water utilities. With recent system enhancements, the BioSentry can now meet the stringent requirements of high-purity water applications in such industries as pharmaceutical, personal health care and semiconductor manufacturing.

Upgrades to the BioSentry include:

- High temperature compatibility for water for injection (WFI) and sanitation requirements
- Use of pharmaceutical-grade materials including a 316L stainless steel flow cell
- Automatic flow control
- Auto-sanitization

The new system is currently being installed for testing at a major U.S. pharmaceutical company as part of their Process Analytical Technology (PAT) program. PAT is a system for designing, analyzing, and controlling manufacturing through timely measurements of critical quality and performance attributes of in-process materials with the goal of ensuring final product quality¹.

Commenting on the new product enhancements, David McCarty, Vice President for JMAR's Sensor Products Group, stated, "The new release of the BioSentry is a major milestone in our product development. Not only have we broadened the scope of markets and applications we can now address, but our core system has evolved to be more robust and easier to maintain."

"These developments in the BioSentry product line are evidence of JMAR's determination and ability to design and deploy application-specific solutions, said Dr. Neil Beer, President and CEO of JMAR. "I believe acceptance of the BioSentry in the pharmaceutical industry will open doors to a host of high-purity water applications, resulting in increased sales and greater market penetration."

1) Reference FDA Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Process Analytical Technology (PAT) Initiative

About JMAR

JMAR Technologies, Inc. is a late-stage technology company with expertise in the development and early commercialization of detection and laser-based technologies for nano-scale imaging, chemical and biological analysis, and fabrication. The Company is leveraging more than a decade of laser and photonics research in developing a portfolio of products with market applications in high interest areas such as homeland security, biological monitoring of water quality, and hazardous materials detection. These technologies represent significant intellectual property which includes more than thirty issued or pending patents.

Contact Information: JMAR Technologies, Inc.
Kathi Kirchmeier
Marketing Communications
Phone: 858-946-6800

This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. Actual results could differ materially from these forward-looking statements as a result of a number of factors, including the uncertainty of acceptance in the market for our products and technologies or the acceptance of our customers' products or technologies which incorporate our products and technologies, the failure of our technology to perform as predicted, competition from alternative technologies, uncertainties as to the size of the markets, cost and margins for JMAR's products, current or future government regulations affecting the use of JMAR's products, the lack of availability of critical components, the degree of protection from future patents, other risks associated with the development or acquisition of new products or technologies and those risks detailed in the Company's Form 10-K for the year ended December 31, 2006 filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. JMAR Technologies, Inc. does not assume any duty to publicly update or revise the material contained herein.